Global Recombinant Erythropoietin Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Erythropoietin Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin.
Recombinant Erythropoietin Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Erythropoietin Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Chronic Kidney Disease and Cancer Related Anemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Erythropoietin Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Erythropoietin Drugs key manufacturers include Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Roche, 3SBio Group, Celltrion, Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd and LG Life Sciences Ltd, etc. Amgen, Johnson & Johnson, Kyowa Hakko Kirin are top 3 players and held % sales share in total in 2022.
Recombinant Erythropoietin Drugs can be divided into rhEPO and Erythropoiesis-Stimulating Agents (ESA), etc. rhEPO is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Erythropoietin Drugs is widely used in various fields, such as Chronic Kidney Disease, Cancer Related Anemia and Others,, etc. Chronic Kidney Disease provides greatest supports to the Recombinant Erythropoietin Drugs industry development. In 2022, global % sales of Recombinant Erythropoietin Drugs went into Chronic Kidney Disease filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Erythropoietin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Chronic Kidney Disease
Cancer Related Anemia
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Erythropoietin Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Erythropoietin Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Erythropoietin Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Erythropoietin Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Erythropoietin Drugs introduction, etc. Recombinant Erythropoietin Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Erythropoietin Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin.
Recombinant Erythropoietin Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Erythropoietin Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Chronic Kidney Disease and Cancer Related Anemia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Erythropoietin Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Erythropoietin Drugs key manufacturers include Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Roche, 3SBio Group, Celltrion, Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd and LG Life Sciences Ltd, etc. Amgen, Johnson & Johnson, Kyowa Hakko Kirin are top 3 players and held % sales share in total in 2022.
Recombinant Erythropoietin Drugs can be divided into rhEPO and Erythropoiesis-Stimulating Agents (ESA), etc. rhEPO is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Erythropoietin Drugs is widely used in various fields, such as Chronic Kidney Disease, Cancer Related Anemia and Others,, etc. Chronic Kidney Disease provides greatest supports to the Recombinant Erythropoietin Drugs industry development. In 2022, global % sales of Recombinant Erythropoietin Drugs went into Chronic Kidney Disease filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Erythropoietin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd
Segment by Type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)
Segment by Application
Chronic Kidney Disease
Cancer Related Anemia
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Erythropoietin Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Erythropoietin Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Erythropoietin Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Erythropoietin Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Erythropoietin Drugs introduction, etc. Recombinant Erythropoietin Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Erythropoietin Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices